Cancer is a scourge on society. One in two Americans will be diagnosed with cancer during their lifetime and one in five will die. The five-year cancer survival rates approach 90% when diagnosed in the earliest stages of the disease versus just 10% in the latest stages.
We believe it doesn’t have to be this way.
Assembled a deep clinical evidence library with data collected from more than 1,200 subjects
More than 20 premier cancer institutions around the world participated in our clinical trials
IONIQ's ProLung Test was awarded “Breakthrough Device Designation” by US FDA for its life-enhancing potential
Robust, growing intellectual portfolio of patents and know-how
IONIQ has been awarded the 2020 Business Excellence Award by Silicon Review. We’re proud of the progress we made last year in our pursuit of a point-of-care (POC) screening device to help counter this nation’s second leading cause of death. Cancer killed more than 600,000 Americans
IONIQ Sciences has been designated as 2020’s ‘Most Innovative Cancer Detection and Diagnostics Technology Firm’ by CV Magazine. Our goal to modernize cancer testing has taken us to exciting heights this year. We resolutely believe in our potential to introduce a ‘breakthrough’ Multi-Cancer Screen that will non-invasively detect the presence of malignancy
We are proud to be a key supporter and member of the newly formed BioHive, a collective representing the life science and healthcare innovation ecosystem. By embracing diversity and collaboration, BioHive has become the fastest-growing life science community in America. And our innovations are improving
